In 1362 patients with acute ischaemic stroke undergoing thrombectomy, edaravone dexborneol vs placebo gave borderline higher 90-day functional independence (55.0% vs 49.6%; RR 1.11, 95% CI 1.00–1.23; P=0.05), with similar serious adverse events (27.2% vs 25.7%).
RCTn = 1,362
Wang et al. Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial